Newsletter: Circulating calprotectin - the power to assess inflammation

Circulating calprotectin
- the power to assess inflammation 3/2024

With the growing demand for circulating calprotectin, its value as a reliable biomarker for detecting and assessing inflammation and infection is increasingly recognised. Gentian has, in response, expanded our global partnerships and welcomed new routine users of the Gentian GCAL® Calprotectin Immunoassay across a variety of healthcare settings.

In this newsletter, we’re excited to share the latest insights on circulating calprotectin and the GCAL® assay, emphasising its significant role in rheumatology and the continuous interest for calprotectin in emergency departments (ED) and intensive care units (ICUs). Calprotectin levels in plasma and serum offer a sensitive approach for autoimmune conditions like rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), as well as for early detection of infection, supporting clinicians in EDs and ICUs.

Advancing rheumatology care with calprotectin

With growing awareness of calprotectin’s importance in rheumatology and related conditions, this biomarker is increasingly recognised for its role in inflammation assessment.

The European Alliance of Associations for Rheumatology (EULAR) and the Paediatric Rheumatology European Society (PReS) now strongly recommend calprotectin as a biomarker in the diagnosis off Still’s disease (previously known as systemic JIA and adult-onset Still’s disease). Calprotectin testing in plasma and serum gives rheumatologists critical insights into the inflammation status from a single blood test, aiding in treatment decisions and monitoring remission, especially in paediatric care where precision is exceptionally necessary.

By incorporating calprotectin testing into routine clinical practice, rheumatologists gain reliable information about disease activity at crucial decision points, such as treatment adjustments and monitoring remission. The significance of this testing is especially pronounced in paediatric rheumatology, where precise and sensitive monitoring of inflammation activity is essential for effective patient care.

GCAL® - Plasma and serum calprotectin

The GCAL^® assay is intended for quantitative determination of calprotectin in plasma and serum as an aid in detection and assessment of inflammation and inflammatory response to infections. GCAL^® is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) that can be applied on a wide range of automated clinical chemistry analysers. Specifically using avian antibodies in this test, results in the distinct benefit ofavoiding common interference (namely rheumatoid factor and HAMA antibodies).

GCAL^® is the first available (since 2019) turbidimetric assay for circulating calprotectin. It is CE-marked and IVDR certified, in addition to other regional registrations.

All kit components are ready to use with calibrator and dedicated controls. Additionally, the reagent kit is available in two different sizes, accommodating the requirements of both smaller laboratories and high-volume routine users.

Contact us

Explore GCAL^® in your clinical practice and lab - fill out the form or send an email to marketing@gentian.com for more information about the product and prices.

This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.